| Lava Therapeutics–Bellevue: investment, 202009 financing round Series C totalling $83m incl new + co-investor BB Pureos Bioventures |
2020-09-17 |
| Lava Therapeutics–Gilde Investment: investment, 202009 financing round Series C totalling $83m incl existing + co-investor Gilde Healthcare |
2020-09-17 |
| Lava Therapeutics–Merck (US): investment, 202009 financing round Series C totalling $83m incl existing + co-investor MRL Ventures Fund LLC |
2020-09-17 |
| Lava Therapeutics–Novo Group: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Novo Ventures |
2020-09-17 |
| Lava Therapeutics–Redmile Group: investment, 202009 financing round Series C totalling $83m incl new + co-investor Redmile Biopharma Investments |
2020-09-17 |
| Lava Therapeutics–Sanofi: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Sanofi Ventures |
2020-09-17 |
| Lava Therapeutics–SEVERAL: investment, 202009 financing round Series C $83m co-led by Novo Ventures + Sanofi Ventures |
2020-09-17 |
| Lava Therapeutics–Versant Ventures: investment, 202009 financing round Series C totalling $83m incl existing + co-investor Versant |
2020-09-17 |
| Lava Therapeutics–Ysios Capital: investment, 202009 financing round Series C totalling $83m incl new + co-investor Ysios Capital |
2020-09-17 |
| Novartis–BioNTech: investment, 202009– acquisition of Novartis GMP Biologics Manufacturing Site in Marburg by BioNTech |
2020-09-17 |
| Dinaqor–KWM Communications: public relations, 202009 service existent by KWM Communications |
2020-09-16 |
| Graphite Bio–Samsara BioCapital: investment, 202009 financing round Series A totalling $45m incl co-investor Samsara BioCapital |
2020-09-16 |
| Graphite Bio–SEVERAL: investment, 202009 financing round Series A $45m led by founding investor Versant Ventures with Samsara BioCapital |
2020-09-16 |
| Graphite Bio–Versant Ventures: investment, 202009 financing round Series A totalling $45m incl founding + lead investor Versant Ventures |
2020-09-16 |
| Moderna–Cabinet Privé de Conseils: public relations, 202009 service existent CPC is Swiss media contact |
2020-09-16 |
| Neogene Therapeutics–EcoR1 Capital: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor EcorR1 Capital |
2020-09-14 |
| Neogene Therapeutics–Jeito Capital: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor Jeito Capital |
2020-09-14 |
| Neogene Therapeutics–Polaris Partners: investment, 202009 financing round Series A totalling $110m incl new + co-investor Polaris Partners |
2020-09-14 |
| Neogene Therapeutics–Pontifax: investment, 202009 financing round Series A totalling $110m incl new + co-investor Pontifax |
2020-09-14 |
| Neogene Therapeutics–SEVERAL: investment, 202009 financing round Series A $110m co-led by EcorR1 Capital + Jeito Capital + Syncona |
2020-09-14 |
| Neogene Therapeutics–Syncona: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor Syncona |
2020-09-14 |
| Neogene Therapeutics–Texas Pacific Group: investment, 202009 financing round Series A totalling $110m incl existing + co-investor TPG |
2020-09-14 |
| Neogene Therapeutics–Two River: investment, 202009 financing round Series A totalling $110m incl existing + co-investor Two River |
2020-09-14 |
| Neogene Therapeutics–Vida Ventures: investment, 202009 financing round Series A totalling $110m incl existing + co-investor Vida Ventures |
2020-09-14 |
| Canopy Biosciences–Bruker: investment, 202009 acquisition €na of Canopy Biosciences LLC by Bruker Corp |
2020-09-11 |
| Korro Bio–Alexandria Real Estate: investment, 202009 financing round Series A totalling $91.5m incl new + co-investor Alexandria Venture Investments |
2020-09-10 |
| Korro Bio–Atlas Venture: investment, 202009 financing round Series A totalling $91.5m incl existing + co-investor Atlas Venture |
2020-09-10 |
| Korro Bio–Citadel: investment, 202009 financing round Series A totalling $91.5m incl new + co-investor Surveyor Capital |
2020-09-10 |
| Korro Bio–Cormorant Asset Management: investment, 202009 financing round Series A totalling $91.5m incl new + co-investor Cormorant |
2020-09-10 |
| Korro Bio–Mitsubishi Chemical: investment, 202009 financing round Series A totalling $91.5m incl new + co-investor MP Healthcare Venture Management |
2020-09-10 |
| Korro Bio–New Enterprise Associates: investment, 202009 financing round Series A totalling $91.5m incl existing + co-investor NEA |
2020-09-10 |
| Korro Bio–Qiming: investment, 202009 financing round Series A totalling $91.5m incl new + co-investor Qiming Venture Partners USA |
2020-09-10 |
| Korro Bio–SEVERAL: investment, 202009 financing round Series A $91.5m led by Wu Capital |
2020-09-10 |
| Korro Bio–Ten Bridge Communications: public relations, 202008 service existent by Ten Bridge |
2020-09-10 |
| Korro Bio–Wu Capital: investment, 202009 financing round Series A totalling $91.5m incl new + lead investor Wu Capital |
2020-09-10 |
| Oncomfort–SEVERAL: investment, 202009 financing round Series A €10m co-led by Debiopharm + Crédit Mutuel Innovation |
2020-09-09 |
| United States (govt)–Intravacc: EV D68 vaccine, 202009– co-development contract up to $9.4m for prophylactic enterovirus D68 vaccine with NIAID |
2020-09-08 |
| Boehringer–BiomX: biomarker discovery, 202009– collab discovery of microbiome-based biomarkers for IBD using XMarker platform |
2020-09-02 |
| Switzerland (govt)–Moderna: mRNA-based vaccines, 202009c– contract for supply of 4.5m doses of Covid-19 vaccine candidate mRNA-1273 |
2020-09-01 |
| Aimmune Therapeutics–Nestlé: investment, 202008– cash tender offer for all remaining shares at $34.5/share representing total equity value of $2.6b |
2020-08-31 |
| Entasis Therapeutics–Innoviva: investment, 202008 private placement totalling $25m incl Innoviva + another institutional investor |
2020-08-28 |
| Entasis Therapeutics–OTHER: investment, 202008 private placement totalling $25m incl Innoviva + another institutional investor |
2020-08-28 |
| Entasis Therapeutics–Ruth Group: public relations, 202008 service existent by The Ruth Group |
2020-08-28 |
| Entasis Therapeutics–SEVERAL: investment, 202008 private placement $25m with 9.346m units at $2.675 to Innoviva + another institutional investor |
2020-08-28 |
| Intact Vascular–Philips: investment, 202008– acquisition $275m upfront + $85m at closing of transaction |
2020-08-27 |
| Triumvira Immunologics–Bayer: investment, 202008 financing round Series A totalling $55m incl new + co-lead investor Leaps by Bayer |
2020-08-27 |
| Triumvira Immunologics–Northpond Ventures: investment, 202008 financing round Series A totalling $55m incl new + co-lead investor Northpond Ventures |
2020-08-27 |
| Triumvira Immunologics–Oceanpine Capital: investment, 202008 financing round Series A totalling $55m incl new + co-investor Oceanpine Capital |
2020-08-27 |
| Triumvira Immunologics–SEVERAL: investment, 202008 financing round Series A $55m co-led by Leaps by Bayer + Northpond Ventures |
2020-08-27 |
| Triumvira Immunologics–Viva Biotech: investment, 202008 financing round Series A totalling $55m incl new + co-investor Viva Biotech Holdings |
2020-08-27 |
| Freenome–SEVERAL: investment, 202008 financing round Series C $270m co-led by Bain Capital Life Sciences + Perceptive Advisors |
2020-08-26 |
| NewAmsterdam Pharma–Forbion: investment, 202008 seed financing round totalling €20m from Forbion + founders |
2020-08-25 |
| NewAmsterdam Pharma–McDougall Communications: public relations, 202008 service existent by McDougall |
2020-08-25 |
| NewAmsterdam Pharma–SEVERAL: investment, 202008 seed financing round €20m from Forbion + founders |
2020-08-25 |
| Takeda–Engitix: antifibrotics, 202008– collab + license agreem up to $500m+ developm for advanced liver diseases incl NASH |
2020-08-25 |
| Univ Guelph–Bruker: NMR spectrometer, 202008 supply existent of 400 MHz NMR spectrometer + Fourier 80 benchtop NRM system |
2020-08-24 |
| Kymera Therapeutics–SEVERAL: investment, 202008 IPO $173.7m+$26.1m with 8.7m+1.3m common shares at $20/share at Nasdaq Global Market |
2020-08-20 |
| Kymera Therapeutics–Verge Scientific Communications: public relations, 202008 service existent by Verge |
2020-08-20 |
| Scienion–Cellink: investment, 202008– acquisition €80m on cash/debt-free basis with €40m in shares + €40m in shares |
2020-08-19 |
| CureVac–Hopp Group: investment, 202008 private placement €100m at $16/share to DH-LT-Investments GmbH + affiliates |
2020-08-18 |
| Mobilion–SEVERAL: investment, 202008 financing round Series B $35m led by aMoon + incl Agilent + IP Group + Hostplus + Cultivation Capital |
2020-08-17 |
| Principia Biopharma–Sanofi: investment, 202008– acquisition $3.68b cash tender offer at $100/share |
2020-08-17 |
| F2G Ltd–Cowen: investment, 202008 financing round totalling $60.8m incl new investor Cowen Healthcare Investments |
2020-08-12 |
| F2G Ltd–SEVERAL: investment, 202008 financing round $60.8m from new investor Cowen Healthcare Investments + existing investors |
2020-08-12 |
| Galapagos–Scipher Medicine: AI-based drug discovery, 202008– collab IBD drug target valuation with excl option rights for developm for Galapagos |
2020-08-12 |
| Atomwise–AME Cloud Ventures: investment, 202008 financing round Series B totalling $123m incl existing + co-investor AME Cloud Ventures |
2020-08-11 |
| Atomwise–B Capital Group: investment, 202008 financing round Series B totalling $123m incl co-lead investor B Capital Group |
2020-08-11 |
| Atomwise–BV: investment, 202008 financing round Series B totalling $123m incl existing + co-investor BV |
2020-08-11 |
| Atomwise–DCVC: investment, 202008 financing round Series B totalling $123m incl existing + co-investor DCVC |
2020-08-11 |
| Atomwise–Dolby Family Ventures: investment, 202008 financing round Series B totalling $123m incl existing + co-investor Dolby Family Ventures |
2020-08-11 |
| Atomwise–OTHER: investment, 202008 financing round Series B totalling $123m incl two top ten global insurance companies as new investors |
2020-08-11 |
| Atomwise–Sanabil Investments: investment, 202008 financing round Series B totalling $123m incl co-lead investor Sanabil |
2020-08-11 |
| Atomwise–SEVERAL: investment, 202008 financing round Series B $123m co-led by B Capital Group + Sanabil Investments |
2020-08-11 |
| Atomwise–Tencent: investment, 202008 financing round Series B totalling $123m incl existing + co-investor Tencent |
2020-08-11 |
| Atomwise–Y Combinator: investment, 202008 financing round Series B totalling $123m incl existing + co-investor Y Combinator |
2020-08-11 |
| Bayer–Atomwise: AI-based drug discovery, 202008 collab existent |
2020-08-11 |
| Bayer–Linklaters: legal services, 202008 supply service legal counsel with regard to acquisition of Kandy Therapeutics by Bayer |
2020-08-11 |
| Bayer–Morgan Stanley: financial services, 202008 supply service financial advisor with regard to acquisition of Kandy Therapeutics by Bayer |
2020-08-11 |
| Bridge Biotherapeutics–Atomwise: AI-based drug discovery, 202008 collab existent |
2020-08-11 |
| Kandy Therapeutics–Goldman Sachs: financial services, 202008 supply service financial advisor with regard to acquisition of Kandy Tx by Bayer |
2020-08-11 |
| Kandy Therapeutics–Goodwin Procter: legal services, 202008 supply service legal counsel with regard to acquisition of Kandy Therapeutics by Bayer |
2020-08-11 |
| Stemonix–Atomwise: AI-based drug discovery, 202008 collab existent |
2020-08-11 |
| Theia Biosciences–Atomwise: AI-based drug discovery, 202008 collab existent joint venture |
2020-08-11 |
| Vairus–Atomwise: AI-based drug discovery, 202008 collab existent joint venture |
2020-08-11 |
| X-37–Atomwise: AI-based drug discovery, 202008 collab existent joint venture |
2020-08-11 |
| CureVac–SEVERAL: investment, 202008 IPO $245.3m with 13.3m+2m common shares at $16/share at Nasdaq Global Market |
2020-08-10 |
| Dyne Therapeutics–Atlas Venture: investment, 202008 financing round totalling $115m incl existing + co-investor Atlas Venture |
2020-08-10 |
| Dyne Therapeutics–Citadel: investment, 202008 financing round totalling $115m incl new + co-lead investor Surveyor Capital |
2020-08-10 |
| Dyne Therapeutics–Forbion: investment, 202008 financing round totalling $115m incl existing + co-investor Forbion |
2020-08-10 |
| Dyne Therapeutics–Franklin Templeton: investment, 202008 financing round totalling $115m incl new + co-investor Franklin Templeton |
2020-08-10 |
| Dyne Therapeutics–Logos Capital: investment, 202008 financing round totalling $115m incl new + co-investor Logos Capital |
2020-08-10 |
| Dyne Therapeutics–MPM Capital: investment, 202008 financing round totalling $115m incl existing + co-investor MPM Capital |
2020-08-10 |
| Dyne Therapeutics–OTHER: investment, 202008 financing round totalling $115m incl new undisclosed institutional co-investor |
2020-08-10 |
| Dyne Therapeutics–SEVERAL: investment, 202008 financing round $115m co-led by new investors Vida Ventures + Surveyor Capital |
2020-08-10 |
| Dyne Therapeutics–Vida Ventures: investment, 202008 financing round totalling $115m incl new + co-lead investor Vida Ventures |
2020-08-10 |
| Dyne Therapeutics–Wellington Management: investment, 202008 financing round totalling $115m incl new + co-investor Wellington Management Company |
2020-08-10 |
| Immunic–SEVERAL: investment, 202008 underwritten public offering $90m+$13.5m with 5m+750k shares common stock at $18/share |
2020-08-10 |
| Pfenex–Ligand: investment, 202008– cash tender offer $438m upfront at $12/share + $78 CVR milestone ANNOUNCED |
2020-08-10 |
| T-Knife–Andera Partners: investment, 202008 financing round Series A totalling €66m incl existing + co-investor Andera Partners |
2020-08-06 |
| T-Knife–Boehringer: investment, 202008 financing round Series A totalling €66m incl existing + co-investor BIVF |
2020-08-06 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
